• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioAtla Inc.

    3/31/26 4:50:45 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    S-8 1 bcab-20260331.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 31, 2026

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    BIOATLA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    85-1922320

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    BioAtla, Inc.

    11085 Torreyana Road

    San Diego, California 92121

    (Address of Principal Executive Offices) (Zip Code)

    2020 Equity Incentive Plan

    Employee Stock Purchase Plan

    (Full title of the plans)

    Jay M. Short, Ph.D.

    Co-Founder, Chief Executive Officer and Chairman

    BioAtla, Inc.

    11085 Torreyana Road

    San Diego, California 92121

    (858) 558-0708

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    David Schulman, Esq.

    Niki Fang, Esq.

     

     

     


     

    Orrick, Herrington & Sutcliffe LLP

    405 Howard Street

    San Francisco, CA 94105

    (415) 773-5700

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 1,538,461 additional shares of common stock under the 2020 Plan and 814,563 additional shares of common stock under the ESPP pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on December 18, 2020 (Registration No. 333-251520), March 24, 2021 (Registration No. 333-254673), March 1, 2022 (Registration No. 333-263120), March 23, 2023 (Registration No. 333-270802), March 26, 2024 (Registration No. 333-278247), and March 28, 2025 (Registration No. 333-286196).

     

     

     


     

    Item 8. Exhibits.

    The following exhibits are filed herewith:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Incorporated by Reference

     

    Exhibit

    Number

    Exhibit Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

     

    Filed
    Herewith

     

     

     

     

     

     

     

     

     

     

     

     

    5.1

    Opinion of Orrick, Herrington & Sutcliffe LLP

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

    Consent of Orrick, Herrington & Sutcliffe LLP (included in Exhibit 5.1)

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

    24.1

    Power of Attorney (included on the signature page of this Registration Statement)

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

    99.1

    2020 Equity Incentive Plan

     

    S-1/A

     

    333-250093

     

    10.01

     

    12/9/2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.2

    Amendment No. 1 to 2020 Equity Incentive Plan

     

    S-8

     

    333-251520

     

    99.2

     

    12/18/2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.3

    Amendment No. 2 to 2020 Equity Incentive Plan

     

    10-K

     

    001-39787

     

    10.26

     

    2/28/2022

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.4

    Employee Stock Purchase Plan

     

    S-1/A

     

    333-250093

     

    10.01

     

    12/9/2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.5

    Amendment No. 1 to Employee Stock Purchase Plan

     

    10-K

     

    001-39787

     

    10.27

     

    2/28/2022

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107

    Filing Fee Table

     

     

     

     

     

     

     

     

     

    X

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 31, 2026.

     

    BIOATLA, INC.

     

    /s/ Jay M. Short, Ph.D.

    Jay M. Short, Ph.D.

    Chief Executive Officer

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jay M. Short, Ph.D. and Christian Vasquez, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

     

     

     

     

     

    SIGNATURE

    TITLE

    DATE

     

     

     

    /s/ Jay M. Short, Ph.D.

    Chief Executive Officer and Director

    March 31, 2026

    Jay M. Short, Ph.D.

    (Principal Executive Officer)

     

     

     

     

    /s/ Christian Vasquez

    Chief Financial Officer

    March 31, 2026

    Christian Vasquez

    (Principal Financial and Accounting Officer)

     

     

     

     

    /s/ Scott Smith

    Director

    March 31, 2026

    Scott Smith

     

     

     

     

     

    /s/ Edward Williams

    Director

    March 31, 2026

    Edward Williams

     

     

     

     

     

    /s/ Lawrence Steinman, M.D.

    Director

    March 31, 2026

    Lawrence Steinman, M.D.

     

     

     

     

     

    /s/ Sylvia McBrinn

    Director

    March 31, 2026

    Sylvia McBrinn

     

     

     

     

     

    /s/ Mary Ann Gray, Ph.D.

    Director

    March 31, 2026

    Mary Ann Gray, Ph.D.

     

     

     

     

     

    /s/ Susan Moran, M.D.

    Director

    March 31, 2026

    Susan Moran, M.D.

     

     

     

     

     

     

     


    Get the next $BCAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    1/13/2026$4.00Buy
    Rodman & Renshaw
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAtla Announces Share Consolidation

    SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the "Share Consolidation") of its common stock, par value $0.0001 per share (the "Common Stock"), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the "Effective Date"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "BCAB" and is expected to begin trading on a split-adjusted basis when the market opens

    3/31/26 4:06:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. "As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and e

    3/31/26 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

    SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of

    3/2/26 7:30:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Sievers Eric was granted 240,000 shares, increasing direct ownership by 67% to 598,705 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    3/12/26 4:08:15 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Short Jay M Phd was granted 430,000 shares, increasing direct ownership by 19% to 2,659,603 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    3/12/26 4:07:56 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Vasquez Christian was granted 240,000 shares, increasing direct ownership by 83% to 530,196 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    3/12/26 4:07:37 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla downgraded by Citizens JMP

    Citizens JMP downgraded BioAtla from Mkt Outperform to Mkt Perform

    8/13/25 8:01:09 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla downgraded by H.C. Wainwright

    H.C. Wainwright downgraded BioAtla from Buy to Neutral

    11/13/24 7:31:56 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    SEC Filings

    View All

    SEC Form S-8 filed by BioAtla Inc.

    S-8 - BioAtla, Inc. (0001826892) (Filer)

    3/31/26 4:50:45 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioAtla, Inc. (0001826892) (Filer)

    3/31/26 4:05:25 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by BioAtla Inc.

    10-K - BioAtla, Inc. (0001826892) (Filer)

    3/31/26 4:05:31 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    1/19/24 4:21:50 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/26/23 7:43:02 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/20/23 6:27:44 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

    SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

    11/14/24 4:00:05 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    10/2/24 4:30:04 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    9/6/24 4:59:38 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    View All

    BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

    SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

    12/21/21 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Financials

    Live finance-specific insights

    View All

    BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. "As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and e

    3/31/26 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell

    11/13/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

    SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 13, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2025 Earnings Conference CallDial-in Numbers: (800)-343-4136 (domestic), (203) 518-9843 (internation

    11/5/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care